Service de Physiologie et d'Explorations Fonctionnelles Pédiatriques, Pôle Enfant Adolescent, CHU de Nice, France.
Allergy. 2011 Jan;66(1):92-100. doi: 10.1111/j.1398-9995.2010.02432.x.
Oral challenges are required to establish the persistence or resolution of IgE-mediated cow's milk allergy (CMA). Determining the appropriate timing for challenging is the main difficulty. The benefit of the basophil activation test (BAT) in predicting a child's reaction to the oral challenge was evaluated and compared to the specific IgE and skin prick tests' (SPT) results.
One hundred and twelve consecutive children with CMA admitted for an oral challenge to reassess their allergy were included. Allergen-induced basophil activation was detected as a CD63-upregulation by flow cytometry.
Thirty-six children (32%) had a positive oral challenge. The percentage of activated basophils in patients with a positive challenge (mean = 20.9; SD = 18.8) was significantly higher than that of patients with a negative challenge (mean = 3.9; SD = 9.8, P < 0.0001), and was well correlated with the eliciting dose of cow's milk (P < 0.0001). The BAT had an efficiency of 90%, a sensitivity of 91%, a specificity of 90%, and positive and negative predictive values of 81% and 96% in detecting persistently allergic patients. The area under the ROC curve was 0.866. These scores were higher than those obtained with SPT and IgE values, whichever positivity cut-point was chosen. Referring to a decisional algorithm combining BAT, specific IgE and SPT allowed the correct identification of 94% of patients as tolerant or persistently allergic to cow's milk proteins (CMP) in our cohort.
The BAT could be a valuable tool in the management of paediatric CMA in addition to specific IgE quantification and SPT, by contributing in determining whether an oral challenge can safely be undertaken.
口服挑战是确定 IgE 介导的牛奶过敏 (CMA) 持续存在或消退所必需的。确定挑战的适当时机是主要难点。评估和比较嗜碱性粒细胞激活试验 (BAT) 在预测儿童对口服挑战的反应方面的益处,并与特异性 IgE 和皮肤点刺试验 (SPT) 的结果进行比较。
纳入 112 例因口服挑战而再次评估过敏的 CMA 连续患儿。通过流式细胞术检测过敏原诱导的嗜碱性粒细胞激活作为 CD63 上调。
36 名儿童 (32%) 口服挑战阳性。阳性挑战患者的激活嗜碱性粒细胞百分比 (均值 = 20.9;SD = 18.8) 明显高于阴性挑战患者 (均值 = 3.9;SD = 9.8,P < 0.0001),与牛致敏剂量呈正相关奶 (P < 0.0001)。BAT 在检测持续过敏患者方面的效率为 90%,灵敏度为 91%,特异性为 90%,阳性和阴性预测值分别为 81%和 96%。ROC 曲线下面积为 0.866。这些评分高于 SPT 和 IgE 值的评分,无论选择哪种阳性切点。结合 BAT、特异性 IgE 和 SPT 的决策算法可以正确识别我们队列中 94%的患者对牛奶蛋白 (CMP) 耐受或持续过敏。
除了特异性 IgE 定量和 SPT 外,BAT 可以成为小儿 CMA 管理的有价值的工具,有助于确定是否可以安全进行口服挑战。